CHARIOT
Research type
Research Study
Full title
A Prescreening Study in the United Kingdom Utilising the CHARIOT Registry to Identify Individuals with Memory Impairment
IRAS ID
161803
Contact name
Khushboo Patel
Contact email
Sponsor organisation
AstraZeneca Pharmaceuticals
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Alzheimer’s disease (AD) is the most prevalent cause of dementia and causes loss of memory and other cognitive abilities, loss of normal function, and ultimately, loss of independence, putting a heavy personal and financial burden on the family and society.
A previous pilot study showed good feasibility in identifying and recruiting individuals with early memory decline from the Cognitive Health in Ageing Register: Investigational, Observational and Trial studies in dementia research (CHARIOT). The purpose of this study is to use CHARIOT to identify people with a gradual decline in memory and who are interested in potentially participating in a clinical drug study, and confirm that they have objective evidence of memory impairment.
Participants may be asked some questions about their medical history and will complete a cognitive test. The participants’ study partner will be asked to fill in a questionnaire which looks at symptoms of early AD. If a participant appears to meet the inclusion criteria, they will be referred to a research study of a new medication for Alzheimer’s Disease.
This study is being carried out in the United Kingdom and approximately 700 participants will take part.
REC name
North of Scotland Research Ethics Committee 1
REC reference
15/NS/0019
Date of REC Opinion
12 Mar 2015
REC opinion
Favourable Opinion